BRIEF published on 11/08/2024 at 08:50, 5 months 1 day ago Gubor Schokoladen lance l'abonnement Bond 2024/2029 Bourse De Francfort Taux D'intérêt Période D'abonnement Fabricant De Chocolat Gubor Bond
PRESS RELEASE published on 11/08/2024 at 08:45, 5 months 1 day ago GUBOR SCHOKOLADEN: Subscription period for Gubor Bond 2024/2029 starts today Subscription period for Gubor Bond 2024/2029, offering 7.5% - 8.5% p.a. interest rate, opens today for EUR 60 million target volume. Details at gubor-anleihe.de Subscription Period Gubor Bond 2024/2029 7.5% - 8.5% Interest Rate EUR 60 Million Volume Gubor-anleihe.de
BRIEF published on 11/06/2024 at 12:19, 5 months 3 days ago Gubor Schokoladen Launches Corporate Bond with 7.5% - 8.5% Interest Capital Market Interest Rate Corporate Bond Gubor Schokoladen Chocolate Manufacturer
BRIEF published on 11/06/2024 at 12:19, 5 months 3 days ago Gubor Schokoladen lance une obligation d'entreprise avec un intérêt de 7,5 à 8,5 % Marché Des Capitaux Taux D'intérêt Obligation D'entreprise Chocolats Gubor Fabricant De Chocolat
PRESS RELEASE published on 11/06/2024 at 12:14, 5 months 3 days ago GUBOR SCHOKOLADEN issues corporate bond with an interest rate of 7.5 - 8.5% p.a. Gubor Schokoladen issues EUR 60 million corporate bond with 7.5 - 8.5% interest rate p.a. For institutional and retail investors. Subscription starts Nov 8, 2024 Investment Interest Rate Deutsche Börse Corporate Bond Gubor Schokoladen
Published on 04/09/2025 at 14:30, 10 minutes ago Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
Published on 04/09/2025 at 14:15, 25 minutes ago Revolve Corporate Update Highlights Several Key Milestones
Published on 04/09/2025 at 14:00, 40 minutes ago Bausch Health, Canada Inc. et l’Alliance pharmaceutique pancanadienne signent une lettre d’intention concernant pour la couverture par les régimes publics d’assurance médicaments du traitement pour l’acné vulgaire (Pr)CABTREO(MC) (gel de phosph
Published on 04/09/2025 at 14:00, 40 minutes ago Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance Sign Letter of Intent for Public Drug Plan Coverage of (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris
Published on 04/09/2025 at 13:45, 55 minutes ago Quartz Commences Drilling at Prodigy High Grade Precious Metals Discovery on Its Maestro Property in British Columbia
Published on 04/09/2025 at 14:10, 30 minutes ago Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
Published on 04/09/2025 at 11:26, 3 hours 14 minutes ago EQS-Adhoc: fox e-mobility AG: Resumption of trading – No challenge to capital resolutions – Legal remedy against the opening of bankruptcy proceedings at the Swiss subsidiary -
Published on 04/09/2025 at 11:24, 3 hours 16 minutes ago Electricité de Strasbourg - Avis de réunion AGO du 14 mai 2025 publié au BALO
Published on 04/09/2025 at 09:00, 5 hours 40 minutes ago STEF : Avis de mise à disposition des comptes annuels 2024
Published on 04/09/2025 at 08:00, 6 hours 40 minutes ago Museum Studio becomes a majority shareholder in Lord Cultural Resources
Published on 04/09/2025 at 08:00, 6 hours 40 minutes ago Museum Studio devient actionnaire majoritaire de Lord Cultural Resources
Published on 04/09/2025 at 07:00, 7 hours 40 minutes ago Biophytis confirme le lancement de l’essai clinique de Phase 2 OBA dans l’obésité
